isunakinra + pembrolizumab

Isunakinra + pembrolizumab is an **investigational combination therapy** consisting of isunakinra, a recombinant IL-1 receptor antagonist (originally EBI-005), and pembrolizumab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Isunakinra blocks IL-1 receptor-mediated inflammation, while pembrolizumab restores T-cell function by inhibiting PD-1, enhancing anti-tumor immunity. This combination is being evaluated in **metastatic or unresectable, locally advanced colorectal cancer (microsatellite stable, high tumor mutational burden, RAS-mutated)** populations typically resistant to immune checkpoint monotherapy. The main mechanism is dual blockade of immunosuppressive pathways, aiming to overcome tumor immune resistance and elicit stronger anti-tumor responses[1][3][5].